Online Inquiry
Metastatic Tumor Model Development
Metastatic tumor models are important experimental tools used to study the metastatic process of prostate cancer. Alfa Cytology is committed to providing one-stop metastatic tumor model development services. Our goal is to provide you with reliable, reproducible and translatable models.
Introduction to Metastatic Tumor Model
Prostate cancer is the second most common cancer and the fifth leading cause of cancer death in men, with a lower mortality rate in the non-metastatic stage. However, unlike limited prostate cancer, metastatic prostate cancer has a poorer prognosis, and advanced tumor metastasis is the leading cause of patient death.
Fig. 1 Vicious cycle of cancer proliferation in the bone microenvironment. (Tae, J. H., et al. 2023)
Bone is one of the most common sites of metastasis in advanced solid cancers, with nearly 60% of prostate cancer patients developing bone metastases. Animal models of bone metastatic prostate cancer are important tools for understanding the characteristics of prostate cancer and finding new targets for future therapeutic agents.
Our Services
At Alfa Cytology, we have established a proven technology platform designed to provide our global customers with efficient and effective prostate cancer metastasis models for prostate cancer research and antitumor drug development. Our team of experts breaks down experimental and technical barriers and focuses on providing customized bone metastatic animal models of prostate cancer, including but not limited to the following.
Table 1. Translational models of prostate cancer bone metastasis
| Cell Line | Inoculation Method | Mouse Strain |
| Human Cell Lines | ||
| DU145 | Intraosseous | Nude and SCID |
| LNCaP | Intraosseous | SCID and SCID/bg |
| LNCaP | Orthotopic | SCID |
| LNCaP C4-2 | Intraosseous | Nude and SCID/bg |
| LNCaP C4-2B | Intraosseous | Nude, SCID, and SCID/bg |
| PC3 | Intraosseous | Nude, CD-1 nude, and SCID |
| Non-Human Cell Lines | ||
| ACE-1 | Intracardiac | Nude |
| ACE-1 | Intraosseous | Nude |
| Human Bone Implant | ||
| LNCaP | Intraosseous | NOD-SCID |
| PC3 | Intraosseous | NOD-SCID |
| DU145 | Intraosseous | NOD-SCI |
| Humanized Bone Sponge | ||
| LNCaP | Intraosseous | NOD-SCID |
| PC3 | Intraosseous | NOD-SCID |
| 3D In Vitro | ||
| LuCaP | Intraosseous | Ragnull and IL-2Rγnull |
Workflow of Metastatic Tumor Model Development
Cell Line Selection
Model Construction
Metastasis Monitoring
Data Reporting
Case Study
PC-3-GFP-derived Metastatic Prostate Cancer Model
Our validated modeling platform offers a highly predictive environment for studying prostate cancer bone metastasis. Designed to support drug discovery and translational research, this system provides an essential tool for testing bone-targeted agents and therapies aimed at mitigating bone-related complications.
- Model Information
Cell Line: PC-3-GFP cell lines
Age: 4-6 weeks
Weight: 16-20 g
Species: BALB/c-nu mice
Sex: Male
Fig. 2 PC-3-GFP-derived prostate cancer models
Our PC-3-GFP metastasis model is created through precise injection into the inferior vena cava (IVC) of male BALB/c-nu mice. Under anesthesia, GFP-labeled human prostate cancer cells are delivered into the IVC to achieve systemic circulation, enabling real-time monitoring of tumor cell seeding and growth, ultimately establishing a model of bone metastatic prostate cancer.
- Evaluation of PC-3-GFP derived Prostate Cancer Models
Following model establishment, survival rates were monitored, and Kaplan-Meier survival curves were generated (Figure 3). Using labeled cells, we perform weekly in vivo imaging to non-invasively track the establishment and growth of bone metastases (Figure 4).
Fig. 3 Fluorescent expression monitoring of PC-3-GFP in BALB/c-nu mice
Fig. 4 Survival analysis of PC-3-GFP derived animal models of prostate cancer
Reference
- Tae, J. H., et al. Animal models of bone metastatic prostate cancer. Investigative and clinical urology. 2023, 64(3): 219-228.
For research use only.